KR100838617B1
(ko)
|
1999-02-10 |
2008-06-16 |
아스트라제네카 아베 |
혈관형성 억제제로서의 퀴나졸린 유도체
|
PE20010306A1
(es)
*
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
EE05180B1
(et)
|
1999-12-24 |
2009-06-15 |
Aventis Pharma Limited |
Asaindooli sisaldav farmatseutiline kompositsioon raviotstarbeliseks kasutamiseks, asaindoolid ning nende kasutamine ravimite valmistamiseks, mis on ette nhtud proteiinikinaasi kataltilise toime prssimiseks
|
DE60106409T2
(de)
|
2000-02-07 |
2006-02-02 |
Bristol-Myers Squibb Co. |
3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
|
AU2001241128A1
(en)
*
|
2000-03-14 |
2001-09-24 |
Fujisawa Pharmaceutical Co. Ltd. |
Novel amide compounds
|
WO2001081348A1
(en)
|
2000-04-25 |
2001-11-01 |
Bristol-Myers Squibb Company |
USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
|
CN1315822C
(zh)
|
2000-08-09 |
2007-05-16 |
阿斯特拉曾尼卡有限公司 |
具有vegf抑制活性的喹啉衍生物
|
BR0113057A
(pt)
|
2000-08-09 |
2003-07-08 |
Astrazeneca Ab |
Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para produzir um efeito antiangiogênico e/ou efeito de redução da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento
|
ES2334641T3
(es)
|
2000-09-01 |
2010-03-15 |
Novartis Vaccines And Diagnostics, Inc. |
Derivados aza heterociclicos y su uso terapeutico.
|
BRPI0113757B8
(pt)
|
2000-09-11 |
2017-11-07 |
Chiron Corp |
derivados de quinolinona como inibidores de tirosina quinase
|
NZ525324A
(en)
|
2000-10-20 |
2005-03-24 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
TWI243164B
(en)
|
2001-02-13 |
2005-11-11 |
Aventis Pharma Gmbh |
Acylated indanyl amines and their use as pharmaceuticals
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
US7642278B2
(en)
|
2001-07-03 |
2010-01-05 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole benzimidazole compounds
|
WO2003004488A1
(en)
*
|
2001-07-03 |
2003-01-16 |
Chiron Corporation |
Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
|
US7101884B2
(en)
|
2001-09-14 |
2006-09-05 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
CA2465247C
(en)
*
|
2001-10-26 |
2010-05-18 |
Aventis Pharmaceuticals Inc. |
Benzimidazoles and analogues and their use as protein kinases inhibitors
|
FR2831536A1
(fr)
*
|
2001-10-26 |
2003-05-02 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
|
FR2831537B1
(fr)
*
|
2001-10-26 |
2008-02-29 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
|
US6897208B2
(en)
*
|
2001-10-26 |
2005-05-24 |
Aventis Pharmaceuticals Inc. |
Benzimidazoles
|
CA2473572C
(en)
|
2002-02-01 |
2011-05-10 |
Astrazeneca Ab |
Quinazoline compounds
|
US7166293B2
(en)
|
2002-03-29 |
2007-01-23 |
Carlsbad Technology, Inc. |
Angiogenesis inhibitors
|
US20050119278A1
(en)
*
|
2002-05-16 |
2005-06-02 |
Che-Ming Teng |
Anti-angiogenesis methods
|
BR0313396A
(pt)
|
2002-08-12 |
2005-06-28 |
Sugen Inc |
3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
|
EP1539754A4
(en)
|
2002-08-23 |
2009-02-25 |
Novartis Vaccines & Diagnostic |
BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
|
WO2004050088A1
(ja)
*
|
2002-12-03 |
2004-06-17 |
Kyowa Hakko Kogyo Co., Ltd. |
Jnk阻害剤
|
KR100730267B1
(ko)
*
|
2002-12-19 |
2007-06-20 |
화이자 인코포레이티드 |
안과 질환 치료에 유용한 단백질 키나제 저해제로서의2-(1h-인다졸-6-일아미노)-벤즈아미드 화합물
|
US7192976B2
(en)
|
2002-12-21 |
2007-03-20 |
Angion Biomedica Corporation |
Small molecule modulators of hepatocyte growth factor (scatter factor) activity
|
AU2004218463B2
(en)
|
2003-03-03 |
2009-07-16 |
Array Biopharma, Inc. |
p38 inhibitors and methods of use thereof
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
JP2006522087A
(ja)
*
|
2003-04-03 |
2006-09-28 |
ファイザー・インク |
Ag013736を含んでなる剤形
|
WO2004092217A1
(en)
*
|
2003-04-17 |
2004-10-28 |
Pfizer Inc. |
Crystal structure of vegfrkd: ligand complexes and methods of use thereof
|
FR2854159B1
(fr)
*
|
2003-04-25 |
2008-01-11 |
Aventis Pharma Sa |
Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
WO2005012256A1
(en)
|
2003-07-22 |
2005-02-10 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
AU2004259012C1
(en)
|
2003-07-23 |
2012-08-02 |
Exelixis, Inc. |
Anaplastic lymphoma kinase modulators and methods of use
|
AU2004260756B2
(en)
|
2003-07-30 |
2010-03-25 |
Kyowa Hakko Kirin Co., Ltd. |
Indazole derivatives
|
CA2518951A1
(en)
*
|
2003-07-30 |
2005-02-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Protein kinase inhibitors
|
CN1842335A
(zh)
*
|
2003-09-04 |
2006-10-04 |
默克公司 |
用于治疗高眼压的眼用组合物
|
US20050164300A1
(en)
*
|
2003-09-15 |
2005-07-28 |
Plexxikon, Inc. |
Molecular scaffolds for kinase ligand development
|
US20050182061A1
(en)
*
|
2003-10-02 |
2005-08-18 |
Jeremy Green |
Phthalimide compounds useful as protein kinase inhibitors
|
CA2544492C
(en)
|
2003-11-07 |
2013-01-29 |
Chiron Corporation |
Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
|
CN100450998C
(zh)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
JP2007511618A
(ja)
*
|
2003-11-19 |
2007-05-10 |
シグナル ファーマシューティカルズ,エルエルシー |
インダゾール化合物およびタンパク質キナーゼ阻害剤としてのその使用方法
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
KR20060114022A
(ko)
|
2004-02-27 |
2006-11-03 |
에프. 호프만-라 로슈 아게 |
인다졸 유도체 및 그들을 함유하는 약학 조성물
|
EP1720855A4
(en)
*
|
2004-03-02 |
2008-12-17 |
Smithkline Beecham Corp |
HEMMER OF ACT ACTIVITY
|
JPWO2005094823A1
(ja)
*
|
2004-03-30 |
2007-08-16 |
協和醗酵工業株式会社 |
Flt−3阻害剤
|
JPWO2005108370A1
(ja)
*
|
2004-04-16 |
2008-03-21 |
味の素株式会社 |
ベンゼン化合物
|
EP1742627A4
(en)
|
2004-05-06 |
2009-08-26 |
Plexxikon Inc |
PDE4B HEMMER AND ITS USE
|
CN1968948A
(zh)
*
|
2004-06-17 |
2007-05-23 |
惠氏公司 |
用于制备促性腺激素释放激素受体拮抗剂的方法
|
KR20070027584A
(ko)
*
|
2004-06-17 |
2007-03-09 |
와이어쓰 |
고나도트로핀 방출 호르몬 수용체 길항제
|
BRPI0514687A
(pt)
*
|
2004-08-26 |
2008-06-17 |
Pfizer |
compostos amino heteroarila como inibidores de proteìna tirosina cinase
|
US7605168B2
(en)
|
2004-09-03 |
2009-10-20 |
Plexxikon, Inc. |
PDE4B inhibitors
|
WO2006030826A1
(ja)
|
2004-09-17 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
医薬組成物
|
EP1647549A1
(en)
*
|
2004-10-14 |
2006-04-19 |
Laboratoire Theramex |
Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
|
CA2586177A1
(en)
*
|
2004-11-02 |
2006-05-11 |
Pfizer Inc. |
Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole
|
KR20070085727A
(ko)
*
|
2004-11-02 |
2007-08-27 |
화이자 인코포레이티드 |
인다졸 화합물의 제조 방법
|
RU2007114112A
(ru)
*
|
2004-11-02 |
2008-12-10 |
Пфайзер Инк. (US) |
Способ получения индазольных соединений
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
FR2878442B1
(fr)
*
|
2004-11-29 |
2008-10-24 |
Aventis Pharma Sa |
THIENO(2,3-c)PYRAZOLES SUBSTITUES, PROCEDE DE PREPARATION, COMPOSITIONS LES CONTENANT ET UTILISATION
|
US20060142247A1
(en)
*
|
2004-12-17 |
2006-06-29 |
Guy Georges |
Tricyclic heterocycles
|
KR101334511B1
(ko)
|
2004-12-30 |
2013-11-29 |
아스텍스 테라퓨틱스 리미티드 |
Cdk, gsk 및 오로라 키나아제의 활성을 조절하는피라졸 화합물
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
ES2552338T3
(es)
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
JP5475234B2
(ja)
|
2005-01-21 |
2014-04-16 |
アステックス・セラピューティクス・リミテッド |
医薬化合物
|
WO2006081230A2
(en)
*
|
2005-01-26 |
2006-08-03 |
Schering Corporation |
3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
|
US7605272B2
(en)
|
2005-01-27 |
2009-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
IGF-1R inhibitor
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
WO2006125130A1
(en)
|
2005-05-17 |
2006-11-23 |
Novartis Ag |
Methods for synthesizing heterocyclic compounds
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
WO2006123223A1
(en)
*
|
2005-05-19 |
2006-11-23 |
Pfizer Inc. |
Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
|
WO2006127587A1
(en)
*
|
2005-05-20 |
2006-11-30 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyridines useful as inhibitors of protein kinase
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
WO2006130673A1
(en)
|
2005-05-31 |
2006-12-07 |
Janssen Pharmaceutica, N.V. |
3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
JP2009517481A
(ja)
|
2005-11-29 |
2009-04-30 |
ノバルティス アクチエンゲゼルシャフト |
キノリノンの製剤
|
TW200732305A
(en)
*
|
2005-12-23 |
2007-09-01 |
Yung Shin Pharmaceutical Ind |
Cancer chemotherapy
|
MY151835A
(en)
|
2006-01-31 |
2014-07-14 |
Array Biopharma Inc |
Kinase inhibitors and methods of use thereof
|
US20090291968A1
(en)
*
|
2006-03-23 |
2009-11-26 |
Guy Georges |
Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
|
GB2453058A
(en)
|
2006-04-04 |
2009-03-25 |
Univ California |
Kinase antagonists
|
WO2007136103A1
(ja)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
EP2036893A4
(en)
|
2006-06-30 |
2011-04-13 |
Kyowa Hakko Kirin Co Ltd |
ABL Kinase Inhibitor
|
US20090209537A1
(en)
|
2006-06-30 |
2009-08-20 |
Kyowa Hakko Kirin Co., Ltd. |
Aurora inhibitors
|
US8519135B2
(en)
|
2006-07-14 |
2013-08-27 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2/CCR9
|
JPWO2008020606A1
(ja)
*
|
2006-08-16 |
2010-01-07 |
協和発酵キリン株式会社 |
血管新生阻害剤
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
CL2007002617A1
(es)
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
EP2119707B1
(en)
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
US20100104567A1
(en)
|
2007-03-05 |
2010-04-29 |
Kyowa Hakko Kirin Co., Ltd. |
Pharmaceutical composition
|
CN101730703B
(zh)
*
|
2007-03-16 |
2012-12-26 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
|
SI2134702T2
(sl)
*
|
2007-04-05 |
2023-12-29 |
Pfizer Products Inc. |
Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih
|
DE602008003055D1
(de)
|
2007-05-31 |
2010-12-02 |
Nerviano Medical Sciences Srl |
Zyklokondensierte Azaindole, die als Kinase-Hemmer wirken
|
KR101969689B1
(ko)
|
2007-07-12 |
2019-04-16 |
케모센트릭스, 인크. |
염증의 치료를 위한 ccr2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
|
WO2009046448A1
(en)
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
AU2008310663A1
(en)
*
|
2007-10-11 |
2009-04-16 |
Vertex Pharmaceuticals Incorporated |
Aryl amides useful as inhibitors of voltage-gated sodium channels
|
WO2009073300A1
(en)
|
2007-11-02 |
2009-06-11 |
Vertex Pharmaceuticals Incorporated |
[1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
|
JP5638244B2
(ja)
|
2007-11-09 |
2014-12-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
AU2009204487C1
(en)
|
2008-01-04 |
2014-10-16 |
Intellikine, Llc |
Certain chemical entities, compositions and methods
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
WO2009114870A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
US8334314B2
(en)
|
2008-04-28 |
2012-12-18 |
Asahi Kasei Pharma Corporation |
Phenylpropionic acid derivative and use thereof
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
WO2010006086A2
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
CN102149379A
(zh)
|
2008-07-10 |
2011-08-10 |
安吉翁生物医药有限公司 |
调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
複素環キナーゼ阻害剤
|
DK2358720T3
(en)
|
2008-10-16 |
2016-06-06 |
Univ California |
Heteroarylkinaseinhibitorer fused-ring
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
SG174125A1
(en)
|
2009-04-02 |
2011-10-28 |
Merck Serono Sa |
Dihydroorotate dehydrogenase inhibitors
|
EP2427195B1
(en)
|
2009-05-07 |
2019-05-01 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
DK2464232T3
(en)
|
2009-08-10 |
2016-01-04 |
Samumed Llc |
INDAZOLE INHIBITORS OF THE WNT SIGNAL ROAD AND THERAPEUTIC APPLICATIONS THEREOF
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
NO3001903T3
(sk)
|
2009-12-21 |
2018-03-24 |
|
|
EP2937345B1
(en)
|
2009-12-29 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
JP2013522292A
(ja)
*
|
2010-03-16 |
2013-06-13 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
インダゾール化合物およびそれらの使用
|
ES2593256T3
(es)
|
2010-05-21 |
2016-12-07 |
Infinity Pharmaceuticals, Inc. |
Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
EP3696195B1
(en)
|
2010-07-23 |
2024-02-14 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環化合物及びその使用
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
EP2651917A1
(en)
|
2010-12-13 |
2013-10-23 |
Novartis AG |
Dimeric iap inhibitors
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
BR112013017670B1
(pt)
|
2011-01-10 |
2022-07-19 |
Infinity Pharmaceuticals, Inc |
Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
BR112013025142A2
(pt)
|
2011-04-01 |
2019-09-24 |
Univ Utah Res Found |
análogos de 3-(1h-benzo{d}imidazol-2-il)-1h-indazol substituído como inibidores da cinase pdk1
|
WO2012144463A1
(ja)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
MX2014000648A
(es)
|
2011-07-19 |
2014-09-25 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos.
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
US8575336B2
(en)
*
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
PE20141371A1
(es)
|
2011-08-29 |
2014-10-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
CN102432595B
(zh)
*
|
2011-09-14 |
2013-09-25 |
湖南有色凯铂生物药业有限公司 |
N-吲哚-1-酰胺类化合物及作为抗癌药物的应用
|
PT2755483T
(pt)
|
2011-09-14 |
2019-02-18 |
Samumed Llc |
Indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização de wnt/β-catenina
|
CA2849995A1
(en)
|
2011-09-27 |
2013-04-04 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
CA2856291C
(en)
|
2011-11-17 |
2020-08-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
EA201491105A1
(ru)
|
2011-12-05 |
2014-09-30 |
Новартис Аг |
Циклические производные мочевины в качестве антагонистов андрогенных рецепторов
|
FR2985257B1
(fr)
*
|
2011-12-28 |
2014-02-14 |
Sanofi Sa |
Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
|
WO2013105022A2
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP3593800A1
(en)
|
2012-05-04 |
2020-01-15 |
Samumed, LLC |
1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
DK2861595T5
(en)
|
2012-06-13 |
2018-01-15 |
Incyte Holdings Corp |
Substituted tricyclic compounds as FGFR inhibitors
|
JP6231262B2
(ja)
*
|
2012-06-20 |
2017-11-15 |
大日本印刷株式会社 |
ピタバスタチンカルシウムの前駆体の製造法
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
BR112015006828A8
(pt)
|
2012-09-26 |
2019-09-17 |
Univ California |
composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CN103804349A
(zh)
*
|
2012-11-01 |
2014-05-21 |
杨子娇 |
一类治疗青光眼的化合物及其用途
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
CA2897400A1
(en)
|
2013-01-08 |
2014-07-17 |
Samumed, Llc |
3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
|
CN104370889A
(zh)
*
|
2013-01-24 |
2015-02-25 |
韩冰 |
一类降低眼压的化合物及其制备方法和用途
|
CA2899968C
(en)
*
|
2013-02-02 |
2016-12-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Substituted 2-aminopyridine protein kinase inhibitor
|
AP2015008618A0
(en)
|
2013-02-19 |
2015-07-31 |
Novartis Ag |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
CA2903979A1
(en)
|
2013-03-14 |
2014-09-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
BR112015022483A2
(pt)
|
2013-03-14 |
2017-07-18 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014147586A1
(en)
|
2013-03-22 |
2014-09-25 |
Novartis Ag |
1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
|
MX367878B
(es)
|
2013-04-19 |
2019-09-10 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
CN103387565B
(zh)
*
|
2013-07-29 |
2014-10-29 |
苏州明锐医药科技有限公司 |
阿西替尼的制备方法
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG11201602445SA
(en)
|
2013-10-04 |
2016-04-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CN103570696B
(zh)
*
|
2013-11-06 |
2016-02-24 |
湖南欧亚生物有限公司 |
一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用
|
WO2015067224A1
(en)
|
2013-11-08 |
2015-05-14 |
Zentiva, K.S. |
Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
JP6523303B2
(ja)
|
2014-01-17 |
2019-05-29 |
ノバルティス アーゲー |
Shp2の活性を阻害するための1−ピリダジン/トリアジン−3−イル−ピペラジン/ピペリジン/ピロリジン誘導体およびその組成物
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
CN105899493B
(zh)
|
2014-01-17 |
2019-03-29 |
诺华股份有限公司 |
用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
|
WO2015143012A1
(en)
|
2014-03-19 |
2015-09-24 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
CN106458920B
(zh)
*
|
2014-03-31 |
2019-02-15 |
千寿制药株式会社 |
炔基吲唑衍生物及其用途
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
KR20170005492A
(ko)
|
2014-05-28 |
2017-01-13 |
아이데닉스 파마슈티칼스 엘엘씨 |
암의 치료를 위한 뉴클레오시드 유도체
|
CN104072484B
(zh)
*
|
2014-07-07 |
2016-07-06 |
渤海大学 |
氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用
|
AR101198A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Pirimidinas 2,5-sustituidas como inhibidores de pde4b
|
AR101196A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Compuestos de pirimidina sustituidos
|
TWI721954B
(zh)
|
2014-08-28 |
2021-03-21 |
日商衛材R&D企管股份有限公司 |
高純度喹啉衍生物及其生產方法
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
BR112017005510A2
(pt)
|
2014-09-17 |
2018-08-14 |
Celgene Quanticel Res Inc |
inibidores da histona-desmetilase.
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
US10508108B2
(en)
|
2014-12-05 |
2019-12-17 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
US10086000B2
(en)
|
2014-12-05 |
2018-10-02 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
EP3226688B1
(en)
|
2014-12-05 |
2020-07-01 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant idh enzymes
|
MA41140A
(fr)
|
2014-12-12 |
2017-10-17 |
Cancer Research Tech Ltd |
Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
EP3789027A1
(en)
|
2015-01-13 |
2021-03-10 |
Kyoto University |
Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
EP3259269B9
(en)
|
2015-02-20 |
2020-03-04 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
SI3263106T1
(sl)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Management Co., Ltd. |
Postopek zatiranja grenkobe derivata kinolina
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
JP6861166B2
(ja)
|
2015-03-27 |
2021-04-21 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
US9580406B2
(en)
|
2015-04-28 |
2017-02-28 |
Signa S.A. De C.V. |
Processes for the preparation of axitinib
|
WO2016189055A1
(en)
|
2015-05-27 |
2016-12-01 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of cancer
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
EP3310774B1
(en)
|
2015-06-19 |
2020-04-29 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
US10308660B2
(en)
|
2015-06-19 |
2019-06-04 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
GB201511382D0
(en)
|
2015-06-29 |
2015-08-12 |
Imp Innovations Ltd |
Novel compounds and their use in therapy
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
WO2017024010A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017024004A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
WO2017024026A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017023989A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024015A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10226448B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
|
WO2017023988A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
TWI696629B
(zh)
|
2015-08-13 |
2020-06-21 |
美商默沙東藥廠 |
作為sting促效劑之環狀雙核苷酸化合物
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
CN108349985A
(zh)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
JP7153331B2
(ja)
*
|
2015-10-07 |
2022-10-14 |
アイビバ バイオファーマ インコーポレイテッド |
皮膚線維性障害を治療するための組成物
|
MX2018004879A
(es)
*
|
2015-10-22 |
2019-02-28 |
Selvita S A |
Nuevos derivados de piridona y su uso como inhibidores de quinasas.
|
EP3371187A4
(en)
|
2015-11-06 |
2019-09-04 |
Samumed, LLC |
2- (1H-INDAZOLE-3-YL) -3H-IMIDAZO [4,5-C] PYRIDINE AND ITS USE AS AN INHIBITOR OF INHIBITOR
|
WO2017106062A1
(en)
|
2015-12-15 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Novel compounds as indoleamine 2,3-dioxygenase inhibitors
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017191599A1
(en)
|
2016-05-04 |
2017-11-09 |
Genoscience Pharma |
Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
|
US10072004B2
(en)
|
2016-06-01 |
2018-09-11 |
Samumed, Llc |
Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
ES2810852T3
(es)
|
2016-06-14 |
2021-03-09 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de shp2
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
CR20190168A
(es)
|
2016-10-04 |
2019-05-17 |
Merck Sharp & Dohme |
Compuestos de benzo[b]tiofeno como agonistas de sting
|
MX2019004616A
(es)
|
2016-10-21 |
2019-11-21 |
Samumed Llc |
Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
|
EP3534878A1
(en)
|
2016-11-07 |
2019-09-11 |
Samumed, LLC |
Single-dose, ready-to-use injectable formulations
|
WO2018091542A1
(en)
|
2016-11-21 |
2018-05-24 |
Idenix Pharmaceuticals Llc |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
EP4134080A1
(en)
|
2016-11-23 |
2023-02-15 |
ChemoCentryx, Inc. |
Ccr2 inhibitors for use in treating renal diseases
|
EP3573718B1
(en)
|
2017-01-27 |
2022-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
ES2891326T3
(es)
|
2017-01-27 |
2022-01-27 |
Janssen Biotech Inc |
Dinucleótidos cíclicos como agonistas de la STING
|
JP6803410B2
(ja)
*
|
2017-02-14 |
2020-12-23 |
富士フイルム株式会社 |
インダゾール化合物の製造方法およびインダゾール化合物
|
WO2018208667A1
(en)
|
2017-05-12 |
2018-11-15 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
CN108947970B
(zh)
*
|
2017-05-18 |
2022-04-05 |
四川大学 |
吲唑类衍生物及其制备方法和用途
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
WO2019027858A1
(en)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER
|
RU2020109328A
(ru)
|
2017-08-04 |
2021-09-06 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
|
PL3474820T3
(pl)
|
2017-08-24 |
2024-05-13 |
Novo Nordisk A/S |
Kompozycje glp-1 i ich zastosowania
|
MA50245A
(fr)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals Inc |
Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
|
WO2019067332A1
(en)
|
2017-09-27 |
2019-04-04 |
Merck Sharp & Dohme Corp. |
COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
|
CA3078809A1
(en)
|
2017-10-11 |
2019-04-18 |
Chemocentryx, Inc. |
Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
|
US20210179607A1
(en)
|
2017-11-01 |
2021-06-17 |
Merck Sharp & Dohme Corp. |
Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
WO2019099294A1
(en)
|
2017-11-14 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
BR112020008258B8
(pt)
|
2017-11-14 |
2023-01-31 |
Merck Sharp & Dohme |
Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
WO2019195063A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
TWI793294B
(zh)
|
2018-04-03 |
2023-02-21 |
美商默沙東有限責任公司 |
Sting促效劑化合物
|
JP2021523118A
(ja)
|
2018-05-04 |
2021-09-02 |
インサイト・コーポレイションIncyte Corporation |
Fgfr阻害剤の塩
|
BR112020022392A2
(pt)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
|
CN110452176A
(zh)
*
|
2018-05-07 |
2019-11-15 |
四川大学 |
吲唑类衍生物及其制备方法和用途
|
US11352320B2
(en)
|
2018-05-31 |
2022-06-07 |
Merck Sharp & Dohme Corp. |
Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
CR20210175A
(es)
|
2018-09-18 |
2021-06-01 |
Nikang Therapeutics Inc |
Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)
|
CN113164776A
(zh)
|
2018-09-25 |
2021-07-23 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
BR112021005513A2
(pt)
|
2018-09-25 |
2021-06-22 |
Black Diamond Therapeutics, Inc. |
derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos
|
CA3113379A1
(en)
|
2018-09-29 |
2020-04-02 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
US20210395240A1
(en)
|
2018-11-01 |
2021-12-23 |
Merck Sharp & Dohme Corp. |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
WO2020096871A1
(en)
|
2018-11-06 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
|
CN111205227A
(zh)
*
|
2018-11-22 |
2020-05-29 |
四川大学 |
3-乙烯基吲唑类衍生物及其制备方法和用途
|
WO2020112581A1
(en)
|
2018-11-28 |
2020-06-04 |
Merck Sharp & Dohme Corp. |
Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
|
JP7532385B2
(ja)
*
|
2019-01-31 |
2024-08-13 |
杏林製薬株式会社 |
15-pgdh阻害薬
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
SG11202110406SA
(en)
|
2019-04-11 |
2021-10-28 |
Angion Biomedica Corp |
Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
|
EP3956321B1
(en)
|
2019-04-18 |
2024-03-20 |
Synthon B.V. |
Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
|
WO2020225413A1
(en)
|
2019-05-09 |
2020-11-12 |
Synthon B.V. |
Pharmaceutical composition comprising axitinib
|
EP3990635A1
(en)
|
2019-06-27 |
2022-05-04 |
Rigontec GmbH |
Design method for optimized rig-i ligands
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
TW202120500A
(zh)
|
2019-08-02 |
2021-06-01 |
美商梅爾莎納醫療公司 |
干擾素基因刺激蛋白(sting)激動劑化合物及用途
|
MX2022001952A
(es)
|
2019-08-15 |
2022-06-02 |
Black Diamond Therapeutics Inc |
Compuestos de alquinil quinazolina.
|
CN112442011B
(zh)
*
|
2019-08-30 |
2023-11-14 |
润佳(苏州)医药科技有限公司 |
一种前药化合物及其在治疗癌症方面的应用
|
CN112442010B
(zh)
*
|
2019-08-30 |
2023-10-03 |
润佳(苏州)医药科技有限公司 |
一类前药化合物及其在治疗癌症方面的应用
|
EP4021912A4
(en)
*
|
2019-08-30 |
2023-08-23 |
Risen (Suzhou) Pharma Tech Co., Ltd. |
TYROSINE KINAS INHIBITOR PRODRUGS FOR THE TREATMENT OF CANCER
|
BR112022007163A2
(pt)
|
2019-10-14 |
2022-08-23 |
Incyte Corp |
Heterociclos bicíclicos como inibidores de fgfr
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
CN112694474B
(zh)
*
|
2019-10-23 |
2022-03-18 |
四川大学 |
吲唑类衍生物及其制备方法和用途
|
JP2023505258A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式複素環
|
IL293001A
(en)
|
2019-12-04 |
2022-07-01 |
Incyte Corp |
Derivatives of fgfr repressors
|
US20230074558A1
(en)
|
2019-12-06 |
2023-03-09 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CN111829859B
(zh)
*
|
2020-01-20 |
2024-01-05 |
北京林业大学 |
一种高效杨树种子透明染色及其三维成像的方法
|
TW202140063A
(zh)
|
2020-02-18 |
2021-11-01 |
丹麥商諾佛 儂迪克股份有限公司 |
醫藥配方
|
BR102020005423A2
(pt)
*
|
2020-03-18 |
2021-09-28 |
Faculdades Catolicas |
Compostos n-acil-hidrazônicos, uso no tratamento de agregopatias degenerativas amiloides e não-amiloides, e composição farmacêutica
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
CN115836054A
(zh)
|
2020-05-06 |
2023-03-21 |
默沙东有限责任公司 |
Il4i1抑制剂和使用方法
|
WO2021232367A1
(zh)
*
|
2020-05-21 |
2021-11-25 |
四川大学 |
3-乙烯基吲唑类衍生物及其制备方法和用途
|
CN113943271B
(zh)
*
|
2020-07-15 |
2023-11-14 |
鲁南制药集团股份有限公司 |
一种阿昔替尼晶型及其制备方法
|
CN112028831A
(zh)
*
|
2020-09-24 |
2020-12-04 |
山东大学 |
一种苯并吡唑类化合物、其制备方法及作为抗肿瘤药物的应用
|
AU2021409561A1
(en)
|
2020-12-22 |
2023-07-06 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
CA3208313A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
EP4323349A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
EP4323350A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式ヘテロ環
|
EP4370522A1
(en)
|
2021-07-14 |
2024-05-22 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
CN115701423A
(zh)
*
|
2021-08-02 |
2023-02-10 |
沈阳化工大学 |
三氟乙基硫醚(亚砜)取代苯类化合物的制备方法及其中间体
|
WO2023192801A1
(en)
|
2022-03-28 |
2023-10-05 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
EP4282415A1
(en)
|
2022-05-26 |
2023-11-29 |
Genepharm S.A. |
A stable tablet composition of axitinib
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2024032584A1
(zh)
*
|
2022-08-08 |
2024-02-15 |
苏州必扬医药科技有限公司 |
一种蛋白酪氨酸激酶抑制剂及其医疗用途
|
WO2024102849A1
(en)
|
2022-11-11 |
2024-05-16 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|